Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › California › Los Angeles
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Los Angeles, CA keessatti
Qorannoo 87 Kansara Qara'a Non-Small Cell f Los Angeles fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 2
- Start Los Angeles /ID# 284999, Los Angeles
- Valkyrie Clinical Trials /ID# 271322, Los Angeles
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Namoota walitti qabaa jiraSadarkaa 3
- Cedars-Sinai Medical Center, Los Angeles
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- The Angeles Clinic and Research Institute (Melanoma), Los Angeles
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Namoota walitti qabaa jiraSadarkaa 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Namoota walitti qabaa jiraSadarkaa 2
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Namoota walitti qabaa jiraSadarkaa 3
- USC Norris Comprehensive Cancer Center ( Site 0205), Los Angeles
- UCLA Jonsson Comprehensive Cancer Center ( Site 0135), Los Angeles
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Namoota walitti qabaa jiraSadarkaa 3
- Cedars-Sinai Medical Center, Los Angeles
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of California Los Angeles, Los Angeles
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- START LA, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Namoota walitti qabaa jiraSadarkaa 3
- Local Institution - 0422, Los Angeles
A Study of PHN-012 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- PHN-012-001 Site, Los Angeles
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Los Angeles
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Namoota walitti qabaa jiraSadarkaa 3
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0033), Los Angeles
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Oncura Health - Good Samaritan, Los Angeles
- California Research Institute, Los Angeles
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 2
- USC Norris Comprehensive Cancer Center, Los Angeles
- Cedars Sinai Medical Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Los Angeles
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- START Los Angeles, LLC, Los Angeles
- LACN Century City, Los Angeles
- Valkyrie Clinical Trials (Additional Site Pharmacy Storage Suite), Los Angeles
- fi 2 dabalataa
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Southern California, Los Angeles
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Research Site, Los Angeles
Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD
Namoota walitti qabaa jiraQorannoo ilaalaa
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- START Los Angeles, Los Angeles
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Study Site, Los Angeles
- Clinical Study Site, Los Angeles
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Namoota walitti qabaa jiraSadarkaa 3
- UCLA Health - Santa Monica Cancer Care, Los Angeles
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- The Angeles clinic - A cedars SINAI AFFILIATE, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Namoota walitti qabaa jiraSadarkaa 1/2
- Valkyrie Clinical Trials, Los Angeles
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Namoota walitti qabaa jiraSadarkaa 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- California Research Institute, Los Angeles
- Los Angeles Cancer Network (LACN), Los Angeles
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 2
- University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Namoota walitti qabaa jiraSadarkaa 1
- Site 105 - START Los Angeles, Los Angeles
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- UCLA Health Bowyer Oncology Center, Los Angeles
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Cedars-Sinai Medical Center, Los Angeles
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- UCLA Oncology Center, Los Angeles
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Los Angeles
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Southern California, Los Angeles
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The Angeles Clinic, Los Angeles
- UCLA, Los Angeles
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Namoota walitti qabaa jiraSadarkaa 3
- USC/Norris Comprehensive Cancer Center, Los Angeles
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Los Angeles
- Research Site, Los Angeles
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
SMP-3124LP in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The Angeles Clinic and Research Institute, Los Angeles
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Cedars-Sinai Cancer at The Angeles Clinic and Research Institute, Los Angeles
- Cedars-Sinai Cancer at SOCC, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 1/2
- UCLA Hematology Oncology - Main Site, Los Angeles
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- UCLA - Hematology/Oncology Clinical Research Unit, Los Angeles
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- University of California Los Angeles Medical Center, Los Angeles
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of California Los Angeles, Los Angeles
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Namoota walitti qabaa jiraSadarkaa 1
- University of California LA, Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Namoota walitti qabaa jiraSadarkaa 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- Cedars Sinai, Los Angeles
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Namoota walitti qabaa jiraSadarkaa 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Valkyrie Clinical Trials, Inc, Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Gilteritinib for the Treatment of ALK NSCLC
Namoota walitti qabaa jiraSadarkaa 1
- Cedars-Sinai Medical Center, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Namoota walitti qabaa jiraSadarkaa 1
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Study of XB010 in Subjects With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Namoota walitti qabaa jiraSadarkaa 1/2
- UCLA Medical Center, Los Angeles
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Start Lacn, Los Angeles
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Southern California, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Cedars-Sinai Medical Center, Los Angeles
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Namoota walitti qabaa jiraSadarkaa 1
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- USA06-0, Los Angeles
- USA16-0, Los Angeles
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Namoota walitti qabaa jiraSadarkaa 3
- UCLA, Los Angeles
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2/3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Cedars-Sinai Medical Center, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Namoota walitti qabaa jira
- Oncology Institute for Hope and Innovation, Los Angeles
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Cedars-Sinai Medical Center, Los Angeles
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- Cedars Sinai Medical Center, Los Angeles
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center, Los Angeles
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Namoota walitti qabaa jiraSadarkaa 1/2
- University of California Los Angeles, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- USC Norris Comprehensive Cancer Center, Los Angeles
Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
GEMINI-NSCLC: NSCLC Biomarker Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- UCLA, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Southern California, Los Angeles
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site 125, Los Angeles
- Research Site 133, Los Angeles
- Research Site 103, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Namoota walitti qabaa jiraSadarkaa 1/2
- UCLA Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- University of Southern California, Los Angeles
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
- Seattle, WAQorannoo 53
Qorannoo biroo Los Angeles keessatti
- Saree (Gosoota Hunda)Qorannoo 74
- Saree OljooQorannoo 73
- Kansarii ProstateQorannoo 61
- Kansarii ColorectalQorannoo 59
- Kansara MetastatikiiQorannoo 57
- Kansarii OvariiQorannoo 50
- Dhibee QaraQorannoo 45
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 42
- Kansarii PancreasQorannoo 35
- Kansa EndometiriyaaliiQorannoo 34
- MelanomaQorannoo 34
- Kansaar Onnee Triple-NegativeQorannoo 27
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.